Latham & Watkins Advises the Underwriters in Public Offering of Common Stock by Vapotherm

Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, priced an underwritten public offering of 3,350,000 shares of its common stock at a price to the public of $26.00 per share. In addition, Vapotherm has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares of its common stock at the public offering price less underwriting discounts and commissions. All of the shares are being offered by Vapotherm. 

Latham & Watkins LLP represents the underwriters in the offering with a New York-based capital markets team led by partner Nathan Ajiashvili, with associates Lindsey Mills, Sandy Kugbei and Regan Devers.